PDSB Stock Analysis: Buy, Sell, or Hold?
PDSB - PDS Biotechnology Corporation Common Stock
$0.96
-0.06 (-5.88%)
▼
5d:
-6.8%
30d:
-28.36%
90d:
+39.13%
HOLD
MODERATE Confidence
Analysis Updated: Jun 16, 2026 12:00 AM ET
Earnings: May 20, 2026
0d
Get Alerted When PDSB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PDSB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PDSB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PDSB is currently trading at $0.96, which is considered oversold relative to its 30-day fair value range of $1.02 to $1.25.
Technical Outlook: Technically, PDSB is in a strong downtrend. The price is currently testing key support at $0.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: PDSB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.50 (+681.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PDSB is in a strong downtrend. The price is currently testing key support at $0.96. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: PDSB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.50 (+681.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.02 -
$1.25
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.9%)
- BULLISH: Trading 681.2% below Wall St target ($7.50)
- CAUTION: 5-day price weakness (-6.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.02 -
$1.25
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.96
Resistance Level
$1.25
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.06
Wall Street Target
$7.50
(+681.2%)
Share & Embed Analysis
Last updated: June 17, 2026 9:42 AM ET
Data refreshes hourly during market hours. Next update: 10:42 AM
Data refreshes hourly during market hours. Next update: 10:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PDSB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 60 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 59 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
